<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03649061</url>
  </required_header>
  <id_info>
    <org_study_id>KCE-16002</org_study_id>
    <secondary_id>2017-004054-41</secondary_id>
    <nct_id>NCT03649061</nct_id>
  </id_info>
  <brief_title>COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA</brief_title>
  <acronym>CareRA2020</acronym>
  <official_title>Effectiveness of a Combination of Methotrexate and a Step Down Glucocorticoid Regimen (COBRA-Slim) for Remission Induction in Patients With Early Rheumatoid Arthritis (RA), With or Without Fast Access to 24 Weeks of Tumor Necrosis Factor (TNF) Blockade in Insufficient Responders, a Randomized, Multicenter, Pragmatic Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>P. Verschueren</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belgium Health Care Knowledge Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the Care in Rheumatoid Arthritis (CareRA) trial (NCT01172639) about 70% of early RA
      patients are in remission at the 2 year evaluation point independent of the combination
      scheme used.

      Interesting to see is that the 30% of insufficient responders can be identified in an early
      stage of the treatment course.

      The purpose of the present study is to investigate if, for patients with an insufficient
      response to a COBRA-Slim regimen, accelerated access to a short course of anti-TNF therapy
      already early after treatment initiation (from w8 until w32) could improve outcomes compared
      to a more traditional treat to target sequence.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Insufficient responders to a COBRA-Slim strategy, defined as not reaching low disease activity based on DAS28 CRP from week 8 until week 32 or not reaching remission based on DAS28 CRP at week 32, will be randomly assigned to one of the two arms.
Randomization will be balanced according to time-point of randomization, baseline (BL) disease activity and Anti-Citrullinated Protein Antibody (ACPA) and Rheumatoid Factor (RF) status to ensure comparability of the treatment groups with respect to these prognostic variables.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC) DAS28 C reactive protein (CRP)</measure>
    <time_frame>over 104 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission</measure>
    <time_frame>at 28 weeks after randomization</time_frame>
    <description>DAS28 CRP&lt;2.6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission</measure>
    <time_frame>at week 104</time_frame>
    <description>DAS28 CRP&lt;2.6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EULAR response</measure>
    <time_frame>at 28 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EULAR response</measure>
    <time_frame>at week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire (HAQ) response</measure>
    <time_frame>at 28 weeks after randomization</time_frame>
    <description>HAQ measures physical function as reported by the patient, total score range from 0-3 of which higher scores represent worse physical function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire (HAQ) response</measure>
    <time_frame>at week 104</time_frame>
    <description>HAQ measures physical function as reported by the patient, total score range from 0-3 of which higher scores represent worse physical function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression</measure>
    <time_frame>at week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression</measure>
    <time_frame>at week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of reported (Serious) Adverse Reactions</measure>
    <time_frame>over 104 weeks</time_frame>
    <description>(Serious) Adverse Reactions will be captured by the investigator using his/her clinical judgement. Number of events will be analysed and described in total and per patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">442</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>standard COBRA-Slim induction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Leflunomide 10mg PO daily added to the COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COBRA-Slim Bio-induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept 50 MG/ML</intervention_name>
    <description>Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme</description>
    <arm_group_label>COBRA-Slim Bio-induction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leflunomide 10 milligram (MG)</intervention_name>
    <description>Leflunomide 10mg PO daily added to the COBRA-Slim scheme</description>
    <arm_group_label>standard COBRA-Slim induction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years and older

          -  Diagnosis of RA as defined by the American College of Rheumatology (ACR)/ European
             League Against Rheumatism (EULAR) 2010 criteria for early RA

          -  Early RA defined by a diagnosis made â‰¤ 1 year ago.

          -  Use a reliable method of contraception for women of childbearing potential to be
             evaluated as in daily clinical practice

          -  Able and willing to give written informed consent and to participate in the study

          -  Understanding and able to write Dutch or French

        Exclusion Criteria:

          -  Previous treatment with:

               -  Methotrexate (MTX) or leflunomide

               -  cyclophosphamide, azathioprine or cyclosporine

               -  sulphasalazine (SSZ) for more than 3 weeks

               -  hydroxychloroquine for more than 6 weeks

               -  oral Glucocorticoids (GC) for more than 4 weeks within 4 months before screening

               -  oral GC at a daily dosage of more than 10 mg prednisone equivalent within 4 weeks
                  before baseline

               -  oral GC at a daily dosage equal to or less than 10 mg prednisone equivalent
                  within 2 weeks before baseline

               -  intra-articular GC within 4 weeks before BL

               -  an investigational drug for the treatment/prevention of RA

          -  History of chronic heart failure

          -  History of severe infections or chronic infection

          -  History of malignant neoplasm within 5 years

          -  Contra indications for GC

          -  Contra indications for TNF blocking agents

          -  Contra indications for MTX or leflunomide

          -  Psoriatic Arthritis

          -  Underlying cardiac, pulmonary, metabolic, renal or gastrointestinal conditions,
             chronic or latent infectious diseases or immune deficiency which in the opinion of the
             investigator places the patient at an unacceptable risk for participation in the study

          -  Pregnancy, breastfeeding or no use of a reliable method of contraception for woman of
             childbearing potential (as in daily clinical practice)

          -  Alcohol or drug abuse

          -  Active tuberculosis (TB)

          -  Latent TB unless adequate prophylactic treatment is given according to local
             guidelines

          -  No access to the Belgian Health Insurance system-
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Verschueren, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Verschueren, MD, PhD</last_name>
    <phone>+32 16 34 25 41</phone>
    <email>patrick.verschueren@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johan Joly, MsC</last_name>
    <phone>+32 16 34 02 58</phone>
    <email>johan.joly@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imelda Ziekenhuis Bonheiden</name>
      <address>
        <city>Bonheiden</city>
        <state>Antwerpen</state>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Els Van Essche, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kathleen Declerck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stijn Michiels, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc De Clerck, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Herentals</name>
      <address>
        <city>Herentals</city>
        <state>Antwerpen</state>
        <zip>2200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luk Corluy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZNA Jan Palfijn</name>
      <address>
        <city>Merksem</city>
        <state>Antwerpen</state>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kurt de Vlam, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Rik Joos, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elke Geens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GHdC Saint Joseph</name>
      <address>
        <city>Gilly</city>
        <state>Henegouwen</state>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Vanden Berghe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reuma centrum Genk</name>
      <address>
        <city>Genk</city>
        <state>Limburg</state>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philip Remans, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reuma Clinic Genk</name>
      <address>
        <city>Genk</city>
        <state>Limburg</state>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johan Vanhoof, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marleen Coppens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascale Volders, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Sileghem, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piet Geusens, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reuma Instituut Hasselt</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Lenaerts, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle De Wergifosse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Langenaken, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLV Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <state>Oost Vlaanderen</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tom Zwaenepoel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle Ravelingien, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bert Vander Cruysse, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Murielle Stubbe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marijke Van Hoydonck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regionaal Ziekenhuis Heilig Hart Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veerle Taelman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Verschueren, MD, PhD</last_name>
      <phone>+32 16 34 25 41</phone>
      <email>patrick.verschueren@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Rene Westhovens, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ St Lucas Brugge</name>
      <address>
        <city>Brugge</city>
        <state>West Vlaanderen</state>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Verbist, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bea Mayaert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mieke Devinck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint Pierre</name>
      <address>
        <city>Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvana Di Romana, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaire Saint Luc (UCL)</name>
      <address>
        <city>Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Durez, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Bernard Lauwerys, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU LiÃ¨ge</name>
      <address>
        <city>LiÃ¨ge</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel Malaise, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Van der Elst K, De Cock D, Vecoven E, Arat S, Meyfroidt S, Joly J, Moons P, Verschueren P, Westhovens R, CareRA Study Group. Are illness perception and coping style associated with the delay between symptom onset and the first general practitioner consultation in early rheumatoid arthritis management? An exploratory study within the CareRA trial. Scand J Rheumatol. 2016;45(3):171-8. doi: 10.3109/03009742.2015.1074278. Epub 2015 Sep 23.</citation>
    <PMID>26399601</PMID>
  </reference>
  <reference>
    <citation>Verschueren P, Esselens G, Westhovens R. Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. Scand J Rheumatol. 2009 May-Jun;38(3):166-72. doi: 10.1080/03009740802484846.</citation>
    <PMID>19169906</PMID>
  </reference>
  <results_reference>
    <citation>Verschueren P, Westhovens R. The use of glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford). 2018 Aug 1;57(8):1316-1317. doi: 10.1093/rheumatology/kex271. Review.</citation>
    <PMID>28968687</PMID>
  </results_reference>
  <results_reference>
    <citation>Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis. 2017 Mar;76(3):511-520. doi: 10.1136/annrheumdis-2016-209212. Epub 2016 Jul 18.</citation>
    <PMID>27432356</PMID>
  </results_reference>
  <results_reference>
    <citation>De Cock D, Van der Elst K, Meyfroidt S, Verschueren P, Westhovens R. The optimal combination therapy for the treatment of early rheumatoid arthritis. Expert Opin Pharmacother. 2015;16(11):1615-25. doi: 10.1517/14656566.2015.1056735. Epub 2015 Jun 10. Review.</citation>
    <PMID>26058860</PMID>
  </results_reference>
  <results_reference>
    <citation>Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Van der Elst K, Meyfroidt S, Westhovens R; CareRA study group. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther. 2015 Apr 9;17:97. doi: 10.1186/s13075-015-0611-8.</citation>
    <PMID>25889222</PMID>
  </results_reference>
  <results_reference>
    <citation>Meyfroidt S, Van der Elst K, De Cock D, Joly J, Westhovens R, Hulscher M, Verschueren P. Patient experiences with intensive combination-treatment strategies with glucocorticoids for early rheumatoid arthritis. Patient Educ Couns. 2015 Mar;98(3):384-90. doi: 10.1016/j.pec.2014.11.011. Epub 2014 Nov 20.</citation>
    <PMID>25483574</PMID>
  </results_reference>
  <results_reference>
    <citation>Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015 Jan;74(1):27-34. doi: 10.1136/annrheumdis-2014-205489. Epub 2014 Oct 30.</citation>
    <PMID>25359382</PMID>
  </results_reference>
  <results_reference>
    <citation>Meyfroidt S, van Hulst L, De Cock D, Van der Elst K, Joly J, Westhovens R, Hulscher M, Verschueren P. Factors influencing the prescription of intensive combination treatment strategies for early rheumatoid arthritis. Scand J Rheumatol. 2014;43(4):265-72. doi: 10.3109/03009742.2013.863382. Epub 2014 Feb 24.</citation>
    <PMID>24559216</PMID>
  </results_reference>
  <results_reference>
    <citation>Westhovens R, Verschueren P. Rheumatoid arthritis: defining remission in patients with RA in clinical practice. Nat Rev Rheumatol. 2012 Aug;8(8):445-7. doi: 10.1038/nrrheum.2012.111. Epub 2012 Jul 3.</citation>
    <PMID>22751567</PMID>
  </results_reference>
  <results_reference>
    <citation>Verschueren P, Westhovens R. Optimal care for early RA patients: the challenge of translating scientific data into clinical practice. Rheumatology (Oxford). 2011 Jul;50(7):1194-200. doi: 10.1093/rheumatology/ker131. Epub 2011 Mar 30. Review.</citation>
    <PMID>21454307</PMID>
  </results_reference>
  <results_reference>
    <citation>Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, Luyten FP, Corluy L, Houssiau FA, Verschueren P. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum. 2007 Dec;56(12):3919-27.</citation>
    <PMID>18050189</PMID>
  </results_reference>
  <results_reference>
    <citation>Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den Brink HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997 Aug 2;350(9074):309-18. Erratum in: Lancet 1998 Jan 17;351(9097):220.</citation>
    <PMID>9251634</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>August 23, 2018</last_update_submitted>
  <last_update_submitted_qc>August 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>P. Verschueren</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>COBRA-Slim</keyword>
  <keyword>Accelerated access to anti-TNF</keyword>
  <keyword>treat to target</keyword>
  <keyword>remission induction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

